Cipla launches new weekly shot for obesity and diabetes in India
Cipla just rolled out Yurpeak, a once-a-week injection approved for treating obesity and type 2 diabetes.
It's the latest way Eli Lilly's popular drug tirzepatide is making its mark in India, now under a fresh brand name.
How Yurpeak works and what to know
Yurpeak targets two key hormone receptors to help manage weight and blood sugar.
It's meant for adults with obesity or those who are overweight with health issues tied to their weight.
The shot comes in six dosage options (2.5 mg to 15 mg) and uses the easy KwikPen device—so no complicated setups.
Who's behind it—and what it means for you
Eli Lilly manufactures Yurpeak, while Cipla handles getting it into clinics across India.
Pricing matches up with Mounjaro, another tirzepatide brand already available.
Cipla says they want this launch to make treatment more accessible and help patients understand their options better.